Evidence development services provider United BioSource (UBC), and decentralised research and consulting services company Thread have launched the next-generation, post-approval research model, SitePlus.
The new research model provides nationwide, direct-to-patient recruitment strategies and enables inclusive, diverse patient population enrolment.
It also minimises the burden on patients and providers taking part in late-stage research.
SitePlus empowers central site study designs that are focused on patients and improves the post-approval research experience for sites by combining UBC’s solutions with Thread’s technology.
Additionally, biopharmaceutical sponsors will be able to contract with UBC as a central research centre, with investigator and coordinator services.
SitePlus connects the central principal investigator and patient coordinating center capabilities of UBC with Thread’s consulting services and unified technology platform for data capture, telehealth, and subject engagement.
UBC president and CEO Bekki Brown said: “Traditional site-only research models are not sufficient to meet the growing demands of regulators, payors, and providers to generate evidence that demonstrates the safety and value of treatments.
“The thread technology platform supports our customer offering by enabling a more flexible approach to patient recruitment and engagement and, ultimately, amplifies the return on evidence generation investment for our clients.”
The companies will now expand their enterprise partnership for another three years. They will also continue to support the decentralised research and eCOA solutions of UBC that enable patient-centered research studies, which will be carried out at home, in the clinic, and on-the-go.
Thread co-founder and CEO John Reites said: “SitePlus will enable UBC’s customers to expand their geographic footprint for study recruitment and offer their research to a broader population supported by a precision screening process.”
Last month, 3H Medi Solution selected Thread for expanding the delivery of decentralised clinical trials (DCTs) and enhancing access to research for Japanese patients.
Decentralised Clinical Trial coverage in Clinical Trials Arena is supported by Huma.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.